Inicio Blog Página 69

NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

0

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

0

The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone.

​   The New England Journal of Medicine: Search Results in Gastroenterology

NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

0

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Gastroenterology

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

0

The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemotherapy alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

0

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

0

Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology

NEJM at ESMO — Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

0

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .

​   The New England Journal of Medicine: Search Results in Dermatology

Ponsegromab for the Treatment of Cancer Cachexia

0

New England Journal of Medicine, Ahead of Print.

​   massmed: New England Journal of Medicine: Table of Contents

NEJM at ESMO — Ponsegromab in Cancer Cachexia

0

New England Journal of Medicine, Ahead of Print.

​   massmed: New England Journal of Medicine: Table of Contents

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

0

New England Journal of Medicine, Ahead of Print.

​   massmed: New England Journal of Medicine: Table of Contents